Achaogen

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

2020	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
2020	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. Appoints Karen Bernstein to the Audit Committee

August 02, 2017 at 04:05 pm EDT

The Board of Achaogen, Inc. appointed Karen Bernstein to the Audit Committee of the Board, effective August 1, 2017.

Latest news about Achaogen

Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	20-06-11	CI
Achaogen, Inc. Went Out of Business	20-05-29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	20-05-29	CI
First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	20-04-22	CI
Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	20-04-21	CI
Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	20-03-30	CI
Motion for Asset Sale Approved for Achaogen, Inc.	20-01-08	CI
Motion for Asset Sale Filed by Achaogen, Inc.	19-12-29	CI
Final DIP Financing Approved for Achaogen, Inc.	19-09-24	CI
Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	19-08-29	CI
First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	19-08-13	CI
Achaogen, Inc. Announces Management Changes	19-07-29	CI
Motion for Asset Sale Approved for Achaogen, Inc.	19-07-23	CI
Motion for Asset Sale Approved for Achaogen, Inc.	19-07-01	CI
Achaogen, Inc. Announces Management Changes	19-06-28	CI
Motion for Asset Sale Approved for Achaogen, Inc.	19-06-26	CI
Cipla USA Inc. entered into a preliminary agreement to acquire worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	19-06-25	CI
Bidding Procedure Approved for Achaogen, Inc.	19-05-01	CI
Achaogen, Inc.(OTCPK:AKAO.Q) dropped from NASDAQ Composite Index	19-04-25	CI
Achaogen, Inc. Enters into A Waiver and First Amendment to the Loan and Security Agreement	19-04-18	CI
Achaogen, Inc.(NasdaqGM:AKAO) dropped from S&P TMI Index	19-04-17	CI
Interim DIP Financing Approved for Achaogen, Inc.	19-04-16	CI
Achaogen, Inc. Filed for Bankruptcy	19-04-15	CI
Achaogen Plans for Near-Term Sale	19-04-15	CI
Motion for Asset Sale Filed by Achaogen, Inc.	19-04-15	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Sector

More about the company

Achaogen

Equities

AKAOQ

US0044491043

Achaogen, Inc. Appoints Karen Bernstein to the Audit Committee

Latest news about Achaogen

Chart Achaogen

Company Profile